supp.fit

Palmitoylethanolamide: study protocols

31 study groups say how much Palmitoylethanolamide participants took a day. These are the doses the studies gave. They are not a recommendation.

Palmitoylethanolamide: what the research found →

Dose per serving from products

60 products in our catalogue print how much Palmitoylethanolamide a serving holds.

Most common: 500 mg to 1 g, 45% of 60 products.

Dose per servingProducts
25 mg or less
1
25 mg to 50 mg
5
50 mg to 100 mg
5
100 mg to 250 mg
6
250 mg to 500 mg
16
500 mg to 1 g
27

Dose per serving from research

31 study groups in 26 studies say how much Palmitoylethanolamide participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 55% of 31 study groups.

Daily doseStudy groups
250 mg to 500 mg
4
500 mg to 1 g
17
1 g to 2.5 g
10

Commonly used together

15 of 31 study groups took Palmitoylethanolamide with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Luteolin
8

31 study groups

Study
Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study
2013 · Palmitoylethanolamide phase (crossover) · Adults with ocular hypertension who had not previously received treatment
600 mg90 days40
Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram
2020 · Group A and Group B, during their PEA treatment period · Adults aged 18 years or older with primary open-angle glaucoma or normal-tension glaucoma
600 mg120 days40
A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
2022 · Active treatment group · Men and women aged 32–75 with type 1 or type 2 diabetes and diabetic-related peripheral neuropathy with neuropathic pain
600 mg8 weeks33
Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial
2022 · palmitoylethanolamide group · Patients in the acute phase of mania; age and sex not stated
1.2 g6 weeks32
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial
2022 · PEA group · Patients with schizophrenia receiving stable-dose risperidone; age and sex not specified
1.2 g8 weeks25
The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial
2022 · PEA · Healthy adult volunteers aged 18 years or older, women and men, with no pain-related diagnosis
1.2 g4 weeks14
Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up
2014 · group A (PEA treatment) · Adults with normal-tension glaucoma; age and sex not reported
600 mg26 weeks—
Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial
2018 · Palmitoylethanolamide group · Patients with DSM-5 major depressive disorder and HAM-D score ≥19; predominantly male
1.2 g6 weeks—
Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study
2018 · ultramicronized palmitoylethanolamide group · Patients with carpal tunnel syndrome awaiting surgery, with sleep disorders and painful symptoms; age and sex not specified
1.2 g——
Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial
2019 · ultramicronized palmitoylethanolamide group · Adults with burning mouth syndrome and burning mouth intensity greater than 4 on the Numeric Rating Scale
1.2 g60 days—
A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
2019 · 300 mg PEA group · Adults with mild to moderate knee osteoarthritis; age range and sex not specified
300 mg8 weeks—
A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis
2019 · 600 mg PEA group · Adults with mild to moderate knee osteoarthritis; age range and sex not specified
600 mg8 weeks—
The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial
2023 · Levagen+ (PEA) group · Adults aged 18–65 years without a stated illness, recruited as otherwise healthy adults
600 mg12 weeks—
Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial
2022 · Intervention group · Adults aged 18–80 with post-COVID-19 anosmia or hyposmia persisting at least 180 days
700 mg90 days130
Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea
2015 · PEA-transpolydatin group · Adolescents and young women aged 16–24 years with primary dysmenorrhea
400 mg10 days110
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
2023 · Combined therapy (um-PEA–LUT: once daily + olfactory training) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19
700 mg90 days76
Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study
2023 · Group 2 · Adults with fibromyalgia
1.2 g12 weeks62
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
2023 · um-PEA–LUT alone (once daily) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19
700 mg90 days48
Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study
2022 · Training-Naïve 1 (PEA-LUT plus olfactory training) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection, without prior olfactory training
700 mg90 days43
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
2023 · um-PEA–LUT alone (twice daily) · Adults aged 18–60 with persistent anosmia or hyposmia after COVID-19
1.4 g90 days40
A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients
2023 · Group B: Standard Therapy + PeaNoc XL · Adults aged 18–60, any sex, with arthritis and DAS 28 score ≥3.2, experiencing joint pain and inflammation
400 mg12 weeks35
Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study
2011 · Group A · Women with chronic pelvic pain related to endometriosis after laparoscopic conservative surgery
800 mg90 days21
The Effects of a Food Supplement, Based on Co-Micronized Palmitoylethanolamide (PEA)-Rutin and Hydroxytyrosol, in Metabolic Syndrome Patients: Preliminary Results
2025 · food supplement (FS) · Adults aged 18–80, women and men, with metabolic syndrome; mean age 65 ± 10 years
720 mg8 weeks19
Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study
2022 · Training-Naïve 2 (PEA-LUT alone) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection, without prior olfactory training
700 mg90 days16
Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study
2022 · Previously trained group (PEA-LUT plus olfactory training) · Adults aged 18–80 with long COVID and persistent anosmia or hyposmia after SARS-CoV-2 infection who had previously undergone olfactory training
700 mg90 days10
Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy
2024 · 10-element combination tablet · Overweight or obese adults with type 2 diabetes and mild-to-moderate painful diabetic neuropathy; mean age 63 years
600 mg26 weeks36
Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial
2024 · PEA group · Healthy male and female university students aged 18 years and older
600 mg6 weeks39
Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial
2022 · LEV · Unvaccinated, nonhospitalized adults aged 19–53 recently diagnosed with COVID-19
1.2 g4 weeks30
Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial
2011 · oral PEA · Patients with primary open-angle glaucoma or ocular hypertension, treated with timolol 0.5%, with intraocular pressure between 19 and 24 mm Hg; age and sex not reported
600 mg60 days—
Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA(B)-ergic activity and cortical plasticity in long COVID-19 syndrome
2023 · PEA-LUT · Adults with fatigue and/or cognitive difficulties after mild COVID-19; age range not reported
1.4 g8 weeks17
Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome
2017 · palmitoylethanolamide/polydatin · Adults with irritable bowel syndrome; age and sex not stated
400 mg12 weeks—